Nanovaccines in cancer immunotherapy: Focusing on dendritic cell targeting
Harun Achmad1, Yousif Saleh Ibrahim2, Muataz Mohammed Al-Taee3
1Department of Pediatric Dentistry, Faculty of Dentistry, Hasanuddin University, Makassar, Indonesia.
Abstract:
Cancer immunotherapy is proposed to eradicate tumors by stimulating host anti-tumor immunity through utilizing various therapeutic approaches. Cancer vaccines have become a promising approach for cancer immunotherapy among the proposed platforms, either alone or in combination with other therapeutic agents. Due to the suboptimal efficacy of cancer vaccines in clinical trials and the advent of nanotechnology in the biomedicine field, scientists developed nanoplatforms, such as various nanoparticles (NPs), cell-derived components, and nanocomplexes, to deliver vaccine components to target cells and tissues, thereby supporting their anti-tumor efficacy and minimizing adverse side effects. To increase the therapeutic effects of nanovaccines in cancer therapy, dendritic cell (DC) targeting through the modulation of the structure of the vaccines, such as using DC-specific ligands, has attracted extensive interest. Here, we reviewed the various forms of nanovaccines in cancer therapy and their therapeutic effects; we highlighted the properties and functions of DCs as the main antigen-presenting cells in immune responses and focused on targeting DCs in developing nanovaccines.
Insights
Cancer nanovaccines utilize nanoparticles to enhance anti-tumor immunity. Targeting dendritic cells (DCs) with these nanovaccines improves cancer therapy efficacy and reduces side effects.
Area of Science:
- Biomedical Science
- Immunology
- Nanotechnology
Background:
- Cancer immunotherapy aims to stimulate the host's immune system to eliminate tumors.
- Cancer vaccines are a key immunotherapy strategy, but often show suboptimal clinical efficacy.
- Nanotechnology offers novel nanoplatforms for improved vaccine delivery and efficacy.
Purpose of the Study:
- To review nanovaccine platforms for cancer therapy.
- To highlight the role of dendritic cells (DCs) in anti-tumor immune responses.
- To focus on DC-targeting strategies for enhancing nanovaccine development.
Main Methods:
- Review of current literature on cancer nanovaccines.
- Analysis of nanoplatforms (nanoparticles, cell-derived components, nanocomplexes) for vaccine delivery.
- Discussion of DC properties and functions as antigen-presenting cells.
Main Results:
- Nanoplatforms can deliver vaccine components to target cells, enhancing anti-tumor efficacy.
- Nanovaccines can minimize adverse side effects compared to conventional therapies.
- Targeting DCs via specific ligands on nanovaccines is a promising strategy.
Conclusions:
- Nanovaccines represent an advanced approach to cancer immunotherapy.
- Optimizing nanovaccine structure for DC targeting is crucial for improving therapeutic outcomes.
- Further research into DC-specific nanovaccine design holds significant potential for cancer treatment.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...